Analysts expect that Reata Pharmaceuticals Inc (NASDAQ:RETA) will post earnings of ($0.82) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Reata Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.99) and the highest is ($0.65). Reata Pharmaceuticals posted earnings per share of ($0.50) during the same quarter last year, which would indicate a negative year-over-year growth rate of 64%. The company is scheduled to report its next quarterly earnings report on Monday, November 12th.
According to Zacks, analysts expect that Reata Pharmaceuticals will report full-year earnings of ($2.59) per share for the current financial year, with EPS estimates ranging from ($2.90) to ($2.26). For the next fiscal year, analysts forecast that the firm will report earnings of ($3.49) per share, with EPS estimates ranging from ($4.16) to ($3.15). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Reata Pharmaceuticals.
Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.34). The company had revenue of $7.57 million during the quarter, compared to analyst estimates of $9.11 million.
NASDAQ:RETA traded up $2.01 during midday trading on Friday, reaching $61.23. 277,425 shares of the company traded hands, compared to its average volume of 294,275. The company has a debt-to-equity ratio of -0.47, a current ratio of 3.09 and a quick ratio of 3.09. Reata Pharmaceuticals has a twelve month low of $19.31 and a twelve month high of $99.50. The firm has a market capitalization of $2.43 billion, a P/E ratio of -30.77 and a beta of 2.79.
In other news, Director James Edward Bass acquired 888 shares of the business’s stock in a transaction dated Wednesday, July 25th. The stock was acquired at an average price of $78.34 per share, for a total transaction of $69,565.92. Following the completion of the acquisition, the director now directly owns 51,543 shares in the company, valued at approximately $4,037,878.62. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Elaine Castellanos sold 7,336 shares of the company’s stock in a transaction on Monday, July 23rd. The shares were sold at an average price of $50.81, for a total value of $372,742.16. Following the completion of the sale, the insider now owns 140 shares of the company’s stock, valued at approximately $7,113.40. The disclosure for this sale can be found here. Corporate insiders own 31.69% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new stake in shares of Reata Pharmaceuticals in the second quarter valued at $6,962,000. Wallace Capital Management Inc. acquired a new stake in shares of Reata Pharmaceuticals in the second quarter valued at $271,000. First Manhattan Co. acquired a new stake in shares of Reata Pharmaceuticals in the second quarter valued at $807,000. Sio Capital Management LLC acquired a new stake in shares of Reata Pharmaceuticals in the second quarter valued at $1,533,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Reata Pharmaceuticals in the second quarter valued at $242,000. Institutional investors and hedge funds own 46.63% of the company’s stock.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Featured Story: What is the Dow Jones Industrial Average (DJIA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.